Jinseob Kim

Mr. Jinseob Kim

Seoul National University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
SLSeunghwa Lee
Seunghwa Lee
JPJungchan Park
Jungchan Park
Rae Woong ParkRae Woong Park
Rae Woong Park
SSSeo Jeong Shin
Seo Jeong Shin
JKJinseob Kim
Jinseob Kim
KYKwangmo Yang
Kwangmo Yang
Studies have reported conflicting results on the association between the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and cancer development. We compared the incidence of cancer between patients using RAAS inhibitors and other antihypertensive drugs. This retrospective observational cohort study used data from seven hospitals in Korea that were converted for use in the Observational Medical Outcomes Partnership Common Data Model. A total of 166,071 patients on antihypertensive therapy across the databases of the seven hospitals were divided into two groups according to the use of RAAS inhibitors. The primary outcome was the occurrence of cancer. A total of 166,071 patients across the databases of the seven hospitals was included in the final analysis; 26,650 (16%) were in the RAAS inhibitors group and 139,421 (84%) in the other antihypertensive drugs group. The meta-analysis of the whole cohort showed a lower incidence of cancer occurrence in the RAAS inhibitor group (9.90 vs. 13.28 per 1000 person years; HR, 0.81; 95% confidence interval [CI], 0.75–0.88). After propensity-score matching, the RAAS inhibitor group consistently showed a lower incidence of cancer (9.90 vs. 13.28 per 1000 person years; HR, 0.86; 95% CI, 0.81–0.91). The patients using RAAS inhibitors showed a lower incidence of cancer compared with those using other antihypertensive drugs. These findings support the association between the use of RAAS inhibitors and cancer occurrence.

Verified
Journal Article
Open access
PDF file
SSSeung In Seo
Seung In Seo
TKTae Jun Kim
Tae Jun Kim
CPChan Hyuk Park
Chan Hyuk Park
CBChangseok Bang
Changseok Bang
KLKyung Joo Lee
Kyung Joo Lee
WSWoon Geon Shin
Woon Geon Shin
Background and aims: Previous studies have reported that metformin use in patients with diabetes mellitus may reduce the risk of colorectal cancer (CRC) incidence and prognosis; however, the evidence is not definite. This population-based cohort study aimed to investigate whether metformin reduces the risk of CRC incidence and prognosis in patients with diabetes mellitus using a common data model of the Korean National Health Insurance Service database from 2002 to 2013. Methods: Patients who used metformin for at least 6 months were defined as metformin users. The primary outcome was CRC incidence, and the secondary outcomes were the all-cause and CRC-specific mortality. Cox proportional hazard model was performed and large-scaled propensity score matching was used to control for potential confounding factors. Results: During the follow-up period of 81,738 person-years, the incidence rates (per 1000 person-years) of CRC were 5.18 and 8.12 in metformin users and non-users, respectively (p = 0.001). In the propensity score matched cohort, the risk of CRC incidence in metformin users was significantly lower than in non-users (hazard ratio (HR), 0.58; 95% CI (confidence interval), 0.47–0.71). In the sensitivity analysis, the lag period extending to 1 year showed similar results (HR: 0.63, 95% CI: 0.51–0.79). The all-cause mortality was significantly lower in metformin users than in non-users (HR: 0.71, 95% CI: 0.64–0.78); CRC-related mortality was also lower among metformin users. However, there was no significant difference (HR: 0.55, 95% CI: 0.26–1.08). Conclusions: Metformin use was associated with a reduced risk of CRC incidence and improved overall survival.

3 August 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
TKTaewan Kim
Taewan Kim
SSSeung In Seo
Seung In Seo
KLKyung Joo Lee
Kyung Joo Lee
CPChan Hyuk Park
Chan Hyuk Park
TKTae Jun Kim
Tae Jun Kim
WSWoon Geon Shin
Woon Geon Shin
Background: Treatment of Helicobacter pylori (HP) has been shown to reduce the risk of gastric cancer (GC) development. However, previous studies have focused on patients at high risk of GC. This study aimed to assess the effect of HP treatment on the incidence of GC in the general population. Materials and Methods: Medical records were obtained from the Common Data Model-converted sample Cohort of the National Health Insurance Service of Korea (NHIS-CDM). The target cohort included those who had been prescribed HP treatment and the comparator cohort included those who had not. The association between HP treatment and the risk of GC development was assessed using the Cox proportional hazard model. The incidences of GC according to the period after HP treatment in different age groups were analyzed using proportional trend tests. Results: After large-scale 1:4 propensity score matching, 2735 and 5328 individuals were included in the target and comparator cohorts, respectively. During the median follow-up of 6.5 years, the GC incidence was lower in the HP treatment cohort than in the comparator cohort, but this was statistically insignificant (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.50–1.13; p-value = 0.19). This trend was also observed among the older age (≥65 years, HR: 0.87; 95% CI: 0.44–1.68; p-value = 0.69) and male cohorts (HR: 0.82; 95% CI: 0.51–1.27; p-value = 0.38). Among 58,684 individuals who were treated for HP from the whole NHIS-CDM cohort, the incidence of GC consistently decreased over time and showed a marked decrease with increasing age (p for trend < 0.05). Conclusions: In all age groups of the general population, HP treatment could be recommended to reduce the risk of GC.

17 November 2023 in Medicine
Verified
Journal Article
Open access
YYYung-Geun Msc Yoo
Yung-Geun Msc Yoo
MLMin-Jung Msc Lim
Min-Jung Msc Lim
JKJinseob Kim
Jinseob Kim
HJHan-Eol Jeong
Han-Eol Jeong
HKHeeJoo BE Ko
HeeJoo BE Ko
JSJu-Young Shin
Ju-Young Shin
There is a lack of studies comparing the risk of cardio-cerebrovascular disease between angiotensin receptor blockers (ARBs) of different half-lives. We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension. To establish a cohort exposed to valsartan, losartan, irbesartan, or telmisartan, we performed propensity score (PS) matching and used an as-treated approach to evaluate exposure. The Cox regression model was employed to calculate hazard ratios, which were based on the incidence rate for each newly occurring event of MI, heart failure, or cerebrovascular disease. These hazard ratios were calculated to compare the risk of MI, heart failure, and cerebrovascular disease associated with valsartan, losartan, and irbesartan in comparison to telmisartan. A PS-matched cohort of 148,229 patients was established for each of valsartan, losartan, irbesartan, or telmisartan. The matched cohort analysis showed that the adjusted hazard ratio (aHRs, 95% confidence interval) for MI was higher for valsartan use (1.39, 1.33–1.45) and losartan use (1.10, 1.05–1.15) but lower for irbesartan use (0.90, 0.86–0.94) compared with the reference (telmisartan). The aHRs for HF were not different among these ARBs (angiotensin receptor blockers). The aHR for cerebrovascular disease was lower for valsartan use (0.85, 0.83–0.87) and losartan use (0.80, 0.78–0.82) but higher for irbesartan use (1.11, 1.09–1.13) compared with the reference. We found differences in the risk of MI and cerebrovascular disease with the use of different ARBs compared to telmisartan use. Valsartan, and losartan with a short half-life, which showed a higher risk of MI, had a lower risk of cerebrovascular disease. Conversely, irbesartan with a long half-life, which showed a lower risk of MI, had a higher risk of cerebrovascular disease.

Verified
Journal Article
Open access
PDF file
MKMi-kyoung Kang
Mi-kyoung Kang
YHYooha Hong
Yooha Hong
HIHee-Jin Im
Hee-Jin Im
JKJinseob Kim
Jinseob Kim
SCSoo-Jin Cho
Soo-Jin Cho
Background: Cluster headache (CH) and obstructive sleep apnea (OSA) are both associated with elevated cardiovascular risk and unhealthy lifestyle factors, including smoking and alcohol use. This study investigated whether the conventional STOP-Bang questionnaire or a modified screening approach incorporating CH-specific clinical features is more useful for identifying treatment-relevant OSA. Methods: We retrospectively analyzed 52 patients with CH who underwent polysomnography (PSG) between January 2020 and December 2025. An apnea–hypopnea index (AHI) of at least 10 events/hour was defined as treatment-relevant OSA. We assessed whether incorporating age at CH onset and the circadian and/or seasonal rhythmicity of CH attacks into the STOP-Bang questionnaire improved screening performance. Results: Of 52 patients, 41 (78.8%) were diagnosed with OSA (AHI ≥ 5) and 25 (48.1%) had treatment-relevant OSA. Patients with treatment-relevant OSA were predominantly male and had a higher median age, body mass index, and age at CH onset. A modified model incorporating CH onset at or after age 30 showed modest improvement than conventional STOP-Bang. At a cut-off point of ≥3, the modified model demonstrated a numerically higher area under the curve (0.804 vs. 0.767) and greater sensitivity (84.0% vs. 76.0%; DeLong p = 0.125), with low specificity (48.1% vs. 55.6%). At a cut-off point of ≥4, the specificity increased to 77.8%. The addition of other clinical characteristics of CH did not further improve the performance. Conclusions: Incorporating CH onset age into the STOP-Bang modestly improved screening for treatment-relevant OSA in CH patients, representing a practical screening refinement warranting external validation.